1344669-87-9Relevant academic research and scientific papers
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure
Follmann, Markus,Ackerstaff, Jens,Redlich, Gorden,Wunder, Frank,Lang, Dieter,Kern, Armin,Fey, Peter,Griebenow, Nils,Kroh, Walter,Becker-Pelster, Eva-Maria,Kretschmer, Axel,Geiss, Volker,Li, Volkhart,Straub, Alexander,Mittendorf, Joachim,Jautelat, Rolf,Schirok, Hartmut,Schlemmer, Karl-Heinz,Lustig, Klemens,Gerisch, Michael,Knorr, Andreas,Tinel, Hanna,Mondritzki, Thomas,Trübel, Hubert,Sandner, Peter,Stasch, Johannes-Peter
, p. 5146 - 5161 (2017/06/28)
The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment option for pulmonary hypertension. Despite its outstanding pharmacological profile, application of riociguat in other cardiovascular indications is limited by its short half-life, necessitating a three times daily dosing regimen. In our efforts to further optimize the compound class, we have uncovered interesting structure-Activity relationships and were able to decrease oxidative metabolism significantly. These studies resulting in the discovery of once daily sGC stimulator vericiguat (compound 24, BAY 1021189), currently in phase 3 trials for chronic heart failure, are now reported.
Substituted annellated pyrimidines and use thereof
-
, (2014/02/15)
The present application relates to novel substituted annellated pyrimidines, methods for production thereof, use thereof alone or in combinations for treating and/or preventing diseases and use thereof for the production of medicinal products for treating
Acidic triazoles as soluble guanylate cyclase stimulators
Roberts, R. Lee,Bradley, A. Paul,Bunnage, E. Mark,England, S. Katherine,Fobian, M. Yvette,Fox, N.A. David,Gymer, Geoff E.,Heasley, Steven E.,Molette, Jerome,Smith, Graham L.,Fairman, David,Schmidt, Michelle A.,Tones, Michael A.,Dack, Kevin N.
, p. 6515 - 6518 (2011/12/04)
A series of acidic triazoles with activity as soluble guanylate cyclase stimulators is described. Incorporation of the CF3 triazole improved the overall physicochemical and drug-like properties of the molecule and is exemplified by compound 25.
